Clinical and Toxicodynamic Evidence that High-Dose Pyrazinamide Is Not More Hepatotoxic than the Low Doses Currently Used

Por Pasipanodya, Jotam G., Gumbo, Tawanda
Publicado em 2010

A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs

Por Pasipanodya, Jotam G., Gumbo, Tawanda
Publicado em 2011

A Meta-Analysis of Self-Administered vs Directly Observed Therapy Effect on Microbiologic Failure, Relapse, and Acquired Drug Resistance in Tuberculosis Patients

Por Pasipanodya, Jotam G., Gumbo, Tawanda
Publicado em 2013

Reply to Moonan and Weis, Seaworth et al, and Nunn and Phillips

Por Pasipanodya, Jotam G., Gumbo, Tawanda
Publicado em 2013

Measuring health-related quality of life in tuberculosis: a systemic review - Response

Por Weis, Stephen E, Pasipanodya, Jotam G
Publicado em 2010

Meta-Analysis of Clinical Studies Supports the Pharmacokinetic Variability Hypothesis for Acquired Drug Resistance and Failure of Antituberculosis Therapy

Por Pasipanodya, Jotam G., Srivastava, Shashikant, Gumbo, Tawanda
Publicado em 2012

Azithromycin Dose To Maximize Efficacy and Suppress Acquired Drug Resistance in Pulmonary Mycobacterium avium Disease

Por Deshpande, Devyani, Pasipanodya, Jotam G., Gumbo, Tawanda
Publicado no Antimicrob Agents Chemother (2016)

pH Conditions under Which Pyrazinamide Works in Humans

Por Srivastava, Shashikant, Pasipanodya, Jotam G., Gumbo, Tawanda
Publicado no Antimicrob Agents Chemother (2017)

Therapy duration and long-term outcomes in extra-pulmonary tuberculosis

Por Pusch, Tobias, Pasipanodya, Jotam G, Hall, Ronald G, Gumbo, Tawanda
Publicado em 2014

In Silico Children and the Glass Mouse Model: Clinical Trial Simulations To Identify and Individualize Optimal Isoniazid Doses in Children with Tuberculosis

Por Jeena, Prakash M., Bishai, William R., Pasipanodya, Jotam G., Gumbo, Tawanda
Publicado em 2011

Multidrug-Resistant Tuberculosis Not Due to Noncompliance but to Between-Patient Pharmacokinetic Variability

Por Srivastava, Shashikant, Pasipanodya, Jotam G., Meek, Claudia, Leff, Richard, Gumbo, Tawanda
Publicado em 2011

Redefining Multidrug-Resistant Tuberculosis Based on Clinical Response to Combination Therapy

Por Gumbo, Tawanda, Pasipanodya, Jotam G., Wash, Peter, Burger, André, McIlleron, Helen
Publicado em 2014

Reply to “Breakpoints and Drug Exposure Are Inevitably Closely Linked”

Por Gumbo, Tawanda, Pasipanodya, Jotam G., Wash, Peter, Burger, André, McIlleron, Helen
Publicado no Antimicrob Agents Chemother (2015)

Pegylated Interferon Fractal Pharmacokinetics: Individualized Dosing for Hepatitis C Virus Infection

Por Jain, Mamta K., Pasipanodya, Jotam G., Alder, Lara, Lee, William M., Gumbo, Tawanda
Publicado em 2013

Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo

Por Deshpande, Devyani, Srivastava, Shashikant, Nuermberger, Eric, Pasipanodya, Jotam G., Swaminathan, Soumya, Gumbo, Tawanda
Publicado no Clin Infect Dis (2016)

A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way

Por Deshpande, Devyani, Srivastava, Shashikant, Nuermberger, Eric, Pasipanodya, Jotam G., Swaminathan, Soumya, Gumbo, Tawanda
Publicado no Clin Infect Dis (2016)

Serum Drug Concentrations Predictive of Pulmonary Tuberculosis Outcomes

Por Pasipanodya, Jotam G., McIlleron, Helen, Burger, André, Wash, Peter A., Smith, Peter, Gumbo, Tawanda
Publicado em 2013

Amikacin Concentrations Predictive of Ototoxicity in Multidrug-Resistant Tuberculosis Patients

Por Modongo, Chawangwa, Pasipanodya, Jotam G., Zetola, Nicola M., Williams, Scott M., Sirugo, Giorgio, Gumbo, Tawanda
Publicado no Antimicrob Agents Chemother (2015)

Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis

Por Srivastava, Shashikant, Modongo, Chawanga, Siyambalapitiyage Dona, Chandima W., Pasipanodya, Jotam G., Deshpande, Devyani, Gumbo, Tawanda
Publicado no Antimicrob Agents Chemother (2016)

A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground

Por Srivastava, Shashikant, Deshpande, Devyani, Pasipanodya, Jotam G., Thomas, Tania, Swaminathan, Soumya, Nuermberger, Eric, Gumbo, Tawanda
Publicado no Clin Infect Dis (2016)